Quantitative Analysis of Behavior in Rotenone-Induced Parkinsonism in Rats Using Force Plate Actimeter

Main Article Content

Stuti Shrestha
Srichan Phornchirasilp
Somjai Nakornchai
Krittiya Thisayakorn


Rotenone is a chemical that has been used to induce Parkinsonism-like behavioral symptoms such as tremor, bradykinesia, rigidity and postural instability in rats. In this study, we used rotenone to induce parkinsonism-like symptoms in rats. Eighteen Wistar rats were randomly divided into three groups: control group, 2.5 mg/kg, rotenone-treated group and 2.5 mg/kg rotenone+10 mg/kg Sinemetâ group. Rotenone was dissolved in soybean oil and injected subcutaneously every day excluding weekends. After 9 doses of soybean oil or rotenone, a series of oral doses of 3% (w/v) acacia or 10 mg/kg Sinemetâ was administered daily for 5 days, followed by a dose of acacia+soybean oil, acacia+rotenone, or Sinemetâ+rotenone. Animal behavior was assessed by using force plate actimeter. The results showed a significant decrease in motor ability of rats injected with rotenone compared to control group. Oral treatment of 10 mg/kg Sinemetâ improved the movement of rotenone-treated rats. Power spectra revealed that the parkinsonian features induced by rotenone possessed the frequency between 0.5-2.5 Hz and 4-12 Hz. This is the first model that applies the behavioral assessment using force plate actimeter in rotenone-induced parkinsonism in rats and thus may be used for evaluating new anti-parkinsonian drugs.


Download data is not yet available.

Article Details

Research Articles


Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376.

Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000;16:135–142.

Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–144.

Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet Neurol. 2004;363:1783–1793.

. Krüger R,Kuhn W,Müller T,Woitalla D,Graeber M,Kösel S,Przuntek H,Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18:106–108.

. Polymeropoulos MH ,Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease.Science. 1997;276(5321):2045-7.

. Kitada T,Asakawa S,Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y,Shimizu N.Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.Nature. 1998;392(6676):605-8.

Sherer TB, Betarbet R, Greenamyre JT Environment, mitochondria, and Parkinson’s disease.Neuroscientist. 2002;8(3):192-7.

Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology.1998; 50(5):1346-50.

Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology. 1993; 43:1150–8.

Saiful IZ, Mohamad RS and Ramlan AA. Study of Rotenone from Derris Roots of Varies Location, Plant Parts and Types of Solvent Used. Adv in Environ Bio. 2014;8(2):445-449.

Betarbet R, Sherer TB, Gillian McK, Monica G, Alexander VP and Greenamyre.JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat neurosci. 2000;3(12):1301-1306.

Sherer TB, Betabert R, Testa CM, Seo BB, Richardson JR, Kin JH, Miller GW, Yagi T, Greenamyre JT. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease. J Neurosci. 2003;23(34): 10756-10764.

Alam A, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136(1):317-24.

Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003;179(1):9–16.

Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis. 2009;34(2):279-90.

Fowler SC, Birkestrand BR, Chen R, Moss SJ, Vorontsova E, Wang G, Zarcone TJ. A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods. 2001;107(1-2):107-24.

Fowler SC. Behavioral Spectoscopy with the Force-Plate Actometer. Curr sep. 2002;20(1):17-22.

Wang G, Fowler SC. Concurrent quantification of tremor and depression of locomotor activity induced in rats by harmaline and physostigmine. Psychopharmacology (Berl). 2001;158(3):273-80.

Zbigniew KB, Sumit S, Lamya MS, Bobby G, Michael AB, Syed FA, Merle GP, Syed ZI. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage. Neuroscience Lett. 2013;541:233–7.

Alexander K, Darryl CG, Alexandra MS, Keri LC, Nadine AT, William GT, Gerlinde AM. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: A cautionary note. Behav Brain Res. 2011;222(1):33-42.

Xiong et al. Edaravone Guards Dopamine Neurons in a Rotenone Model for Parkinson's Disease. PLoS One. 2011;6(6):e20677